P53 protein variants and therapeutic uses thereof

US6933373B2 · kind B2 · utility

Assignee

• AVENTIS PHARMA S.A. · FR

Inventors

• Emmanuel Conseiller · Paris, FR
• Laurent Bracco · Paris, FR

Key dates

• Filing date: Oct 3, 2001
• Grant date: Aug 23, 2005
• Expiry date: Feb 16, 2022

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/828
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Proteins derived from the product of tumor suppressor gene p53 and having enhanced functions for therapeutical use are disclosed. The proteins advantageously have enhanced tumour suppressor and programmed cell death inducer functions, particularly in proliferative disease contexts where wild-type p53 protein is inactivated. Nucleic acids coding for such molecules, vectors containing same, and therapeutical use thereof, particularly in gene therapy, are also disclosed.